BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ:CELG) today announced that its next-generation IMiD® immunomodulatory compound, pomalidomide was evaluated in two separate investigational trials of patients with multiple myeloma (MM) who were relapsed or refractory after treatment with REVLIMID® or REVLIMID and bortezomib. Data were presented at the 51st American Society of Hematology meeting in New Orleans, LA.
